SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Revance Therapeutics, Inc. – ‘10-Q’ for 9/30/15 – ‘EX-101.SCH’

On:  Tuesday, 11/10/15, at 5:11pm ET   ·   For:  9/30/15   ·   Accession #:  1479290-15-10   ·   File #:  1-36297

Previous ‘10-Q’:  ‘10-Q’ on 8/7/15 for 6/30/15   ·   Next:  ‘10-Q’ on 5/10/16 for 3/31/16   ·   Latest:  ‘10-Q’ on 11/8/23 for 9/30/23   ·   8 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

11/10/15  Revance Therapeutics, Inc.        10-Q        9/30/15   66:5.6M

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    644K 
 2: EX-10.1     Material Contract                                   HTML     28K 
 3: EX-10.2     Material Contract                                   HTML     68K 
 4: EX-10.3     Material Contract                                   HTML     64K 
 5: EX-10.4     Material Contract                                   HTML     70K 
 6: EX-10.5     Material Contract                                   HTML     68K 
 7: EX-10.6     Material Contract                                   HTML     70K 
 8: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 9: EX-31.2     Certification -- §302 - SOA'02                      HTML     27K 
10: EX-32.1     Certification -- §906 - SOA'02                      HTML     23K 
11: EX-32.2     Certification -- §906 - SOA'02                      HTML     23K 
45: R1          Document and Entity Information                     HTML     39K 
35: R2          Condensed Consolidated Balance Sheets               HTML     99K 
43: R3          Condensed Consolidated Balance Sheets               HTML     31K 
                (Parenthetical)                                                  
48: R4          Condensed Consolidated Statement of Operations and  HTML     92K 
                Comprehensive Loss                                               
61: R5          Consolidated Statements of Cash Flows               HTML    171K 
37: R6          The Company and Basis of Presentation               HTML     36K 
42: R7          Summary of Significant Accounting Policies          HTML     39K 
32: R8          Medicis Settlement                                  HTML     30K 
25: R9          Cash Equivalents and Investments                    HTML     82K 
62: R10         Fair Value Measurements                             HTML     82K 
50: R11         Notes Payable and Financing Obligation              HTML     41K 
49: R12         Convertible Notes, Warrants, and Related            HTML     26K 
                Derivatives                                                      
54: R13         Interest Expense                                    HTML     62K 
55: R14         Commitments and Contingencies                       HTML     40K 
53: R15         Warrants                                            HTML     22K 
56: R16         Equity                                              HTML    105K 
44: R17         Net Loss per Share Attributable to Common           HTML     62K 
                Stockholders                                                     
46: R18         Subsequent Events                                   HTML     25K 
52: R19         Summary of Significant Accounting Policies          HTML     52K 
                (Policies)                                                       
66: R20         Cash Equivalents and Investments (Tables)           HTML     78K 
58: R21         Fair Value Measurements (Tables)                    HTML     79K 
39: R22         Notes Payable and Financing Obligation (Tables)     HTML     27K 
51: R23         Interest Expense (Tables)                           HTML     60K 
41: R24         Commitments and Contingencies (Tables)              HTML     28K 
22: R25         Equity (Tables)                                     HTML     92K 
59: R26         Net Loss per Share Attributable to Common           HTML     62K 
                Stockholders (Tables)                                            
63: R27         The Company and Basis of Presentation - Additional  HTML     60K 
                Information (Detail)                                             
28: R28         Medicis Settlement - Additional Information         HTML     49K 
                (Detail)                                                         
27: R29         Cash Equivalents and Investments (Details)          HTML     44K 
30: R30         Fair Value Measurements - Schedule of Fair Value    HTML     53K 
                of Financial Instruments (Detail)                                
31: R31         Fair Value Measurements - Summary of Changes in     HTML     27K 
                Fair Value of Financial Instruments (Detail)                     
33: R32         Notes Payable and Financing Obligation - Hercules   HTML     54K 
                Notes Payable (Detail)                                           
21: R33         Notes Payable and Financing Obligation - Essex      HTML     58K 
                Capital Notes (Detail)                                           
57: R34         Notes Payable and Financing Obligation - Summary    HTML     29K 
                of Aggregate Total Future Minimum Lease Payments                 
                under the Financing Obligation (Detail)                          
38: R35         Convertible Notes, Warrants, and Related            HTML     61K 
                Derivatives - Additional Information (Detail)                    
40: R36         Interest Expense - Summary of Interest Expense by   HTML     42K 
                Cash and Non-Cash Components (Detail)                            
24: R37         Commitments and Contingencies - Additional          HTML     34K 
                Information (Detail)                                             
65: R38         Commitments and Contingencies - Schedule of Future  HTML     38K 
                Minimum Lease Payments under Non-Cancelable                      
                Operating Leases (Detail)                                        
18: R39         Warrants - Additional Information (Detail)          HTML     28K 
34: R40         Equity - Additional Information (Detail)            HTML     69K 
60: R41         Equity - Fair Value Assumptions (Details)           HTML     44K 
23: R42         Equity - Schedule of Stock-based Compensation       HTML     30K 
                Expense (Details)                                                
26: R43         Equity - Schedule of Accumulated Other              HTML     33K 
                Comprehensive Income (Details)                                   
29: R44         Net Loss per Share Attributable to Common           HTML     45K 
                Stockholders - Schedule of Computation of Basic                  
                and Diluted Net Income (Loss) Per Share                          
                Attributable to Common Stockholders (Detail)                     
36: R45         Net Loss per Share Attributable to Common           HTML     34K 
                Stockholders - Summary of Common Stock Equivalents               
                Excluded from Computation of Diluted Net Income                  
                (Loss) Per Share (Detail)                                        
20: R46         Subsequent Events (Details)                         HTML     46K 
64: XML         IDEA XML File -- Filing Summary                      XML    106K 
19: EXCEL       IDEA Workbook of Financial Reports                  XLSX     58K 
12: EX-101.INS  XBRL Instance -- rvnc-20150930                       XML   1.30M 
14: EX-101.CAL  XBRL Calculations -- rvnc-20150930_cal               XML    173K 
15: EX-101.DEF  XBRL Definitions -- rvnc-20150930_def                XML    354K 
16: EX-101.LAB  XBRL Labels -- rvnc-20150930_lab                     XML   1.10M 
17: EX-101.PRE  XBRL Presentations -- rvnc-20150930_pre              XML    636K 
13: EX-101.SCH  XBRL Schema -- rvnc-20150930                         XSD    123K 
47: ZIP         XBRL Zipped Folder -- 0001479290-15-000010-xbrl      Zip    149K

‘EX-101.SCH’   —   XBRL Schema — rvnc-20150930

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- XBRL Document Created with Wdesk from Workiva -->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.revance.com/20150930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:rvnc="http://www.revance.com/20150930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
<xsd:import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd"/>
<xsd:import namespace="http://fasb.org/us-roles/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-roles-2015-01-31.xsd"/>
<xsd:import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2015-01-31" schemaLocation="http://xbrl.sec.gov/exch/2015/exch-2015-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvnc-20150930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvnc-20150930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvnc-20150930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvnc-20150930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="CashEquivalentsAndInvestments" roleURI="http://www.revance.com/role/CashEquivalentsAndInvestments">
<link:definition> 2104100 - Disclosure - Cash Equivalents and Investments </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CashEquivalentsAndInvestmentsDetails" roleURI="http://www.revance.com/role/CashEquivalentsAndInvestmentsDetails">
<link:definition> 2404402 - Disclosure - Cash Equivalents and Investments (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CashEquivalentsAndInvestmentsTables" roleURI="http://www.revance.com/role/CashEquivalentsAndInvestmentsTables">
<link:definition> 2304301 - Disclosure - Cash Equivalents and Investments (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsAndContingencies" roleURI="http://www.revance.com/role/CommitmentsAndContingencies">
<link:definition> 2109100 - Disclosure - Commitments and Contingencies </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<link:definition> 2409402 - Disclosure - Commitments and Contingencies - Additional Information (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetail" roleURI="http://www.revance.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetail">
<link:definition> 2409403 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.revance.com/role/CommitmentsAndContingenciesTables">
<link:definition> 2309301 - Disclosure - Commitments and Contingencies (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CompanyAndBasisOfPresentation" roleURI="http://www.revance.com/role/CompanyAndBasisOfPresentation">
<link:definition> 2101100 - Disclosure - The Company and Basis of Presentation </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CompanyAndBasisOfPresentationAdditionalInformationDetail" roleURI="http://www.revance.com/role/CompanyAndBasisOfPresentationAdditionalInformationDetail">
<link:definition> 2401401 - Disclosure - The Company and Basis of Presentation - Additional Information (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.revance.com/role/CondensedConsolidatedBalanceSheets">
<link:definition> 1001000 - Statement - Condensed Consolidated Balance Sheets </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.revance.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<link:definition> 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" roleURI="http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLoss">
<link:definition> 1002000 - Statement - Condensed Consolidated Statement of Operations and Comprehensive Loss </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.revance.com/role/ConsolidatedStatementsOfCashFlows">
<link:definition> 1004000 - Statement - Consolidated Statements of Cash Flows </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="ConvertibleNotesWarrantsAndRelatedDerivatives" roleURI="http://www.revance.com/role/ConvertibleNotesWarrantsAndRelatedDerivatives">
<link:definition> 2107100 - Disclosure - Convertible Notes, Warrants, and Related Derivatives </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="ConvertibleNotesWarrantsAndRelatedDerivativesAdditionalInformationDetail" roleURI="http://www.revance.com/role/ConvertibleNotesWarrantsAndRelatedDerivativesAdditionalInformationDetail">
<link:definition> 2407401 - Disclosure - Convertible Notes, Warrants, and Related Derivatives - Additional Information (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="DocumentAndEntityInformation" roleURI="http://www.revance.com/role/DocumentAndEntityInformation">
<link:definition> 0001000 - Document - Document and Entity Information </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="Equity" roleURI="http://www.revance.com/role/Equity">
<link:definition> 2111100 - Disclosure - Equity </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="EquityAdditionalInformationDetail" roleURI="http://www.revance.com/role/EquityAdditionalInformationDetail">
<link:definition> 2411402 - Disclosure - Equity - Additional Information (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="EquityFairValueAssumptionsDetails" roleURI="http://www.revance.com/role/EquityFairValueAssumptionsDetails">
<link:definition> 2411403 - Disclosure - Equity - Fair Value Assumptions (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="EquityScheduleOfAccumulatedOtherComprehensiveIncomeDetails" roleURI="http://www.revance.com/role/EquityScheduleOfAccumulatedOtherComprehensiveIncomeDetails">
<link:definition> 2411405 - Disclosure - Equity - Schedule of Accumulated Other Comprehensive Income (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="EquityScheduleOfStockBasedCompensationExpenseDetails" roleURI="http://www.revance.com/role/EquityScheduleOfStockBasedCompensationExpenseDetails">
<link:definition> 2411404 - Disclosure - Equity - Schedule of Stock-based Compensation Expense (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="EquityTables" roleURI="http://www.revance.com/role/EquityTables">
<link:definition> 2311301 - Disclosure - Equity (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="FairValueMeasurements" roleURI="http://www.revance.com/role/FairValueMeasurements">
<link:definition> 2105100 - Disclosure - Fair Value Measurements </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" roleURI="http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail">
<link:definition> 2405402 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" roleURI="http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail">
<link:definition> 2405403 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="FairValueMeasurementsTables" roleURI="http://www.revance.com/role/FairValueMeasurementsTables">
<link:definition> 2305301 - Disclosure - Fair Value Measurements (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="InterestExpense" roleURI="http://www.revance.com/role/InterestExpense">
<link:definition> 2108100 - Disclosure - Interest Expense </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="InterestExpenseSummaryOfInterestExpenseByCashAndNonCashComponentsDetail" roleURI="http://www.revance.com/role/InterestExpenseSummaryOfInterestExpenseByCashAndNonCashComponentsDetail">
<link:definition> 2408402 - Disclosure - Interest Expense - Summary of Interest Expense by Cash and Non-Cash Components (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="InterestExpenseTables" roleURI="http://www.revance.com/role/InterestExpenseTables">
<link:definition> 2308301 - Disclosure - Interest Expense (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="MedicisSettlement" roleURI="http://www.revance.com/role/MedicisSettlement">
<link:definition> 2103100 - Disclosure - Medicis Settlement </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="MedicisSettlementAdditionalInformationDetail" roleURI="http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail">
<link:definition> 2403401 - Disclosure - Medicis Settlement - Additional Information (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="NetLossPerShareAttributableToCommonStockholders" roleURI="http://www.revance.com/role/NetLossPerShareAttributableToCommonStockholders">
<link:definition> 2112100 - Disclosure - Net Loss per Share Attributable to Common Stockholders </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="NetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetIncomeLossPerShareAttributableToCommonStockholdersDetail" roleURI="http://www.revance.com/role/NetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetIncomeLossPerShareAttributableToCommonStockholdersDetail">
<link:definition> 2412402 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="NetLossPerShareAttributableToCommonStockholdersSummaryOfCommonStockEquivalentsExcludedFromComputationOfDilutedNetIncomeLossPerShareDetail" roleURI="http://www.revance.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfCommonStockEquivalentsExcludedFromComputationOfDilutedNetIncomeLossPerShareDetail">
<link:definition> 2412403 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="NetLossPerShareAttributableToCommonStockholdersTables" roleURI="http://www.revance.com/role/NetLossPerShareAttributableToCommonStockholdersTables">
<link:definition> 2312301 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="NotesPayableAndFinancingObligation" roleURI="http://www.revance.com/role/NotesPayableAndFinancingObligation">
<link:definition> 2106100 - Disclosure - Notes Payable and Financing Obligation </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="NotesPayableAndFinancingObligationEssexCapitalNotesDetail" roleURI="http://www.revance.com/role/NotesPayableAndFinancingObligationEssexCapitalNotesDetail">
<link:definition> 2406403 - Disclosure - Notes Payable and Financing Obligation - Essex Capital Notes (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="NotesPayableAndFinancingObligationHerculesNotesPayableDetail" roleURI="http://www.revance.com/role/NotesPayableAndFinancingObligationHerculesNotesPayableDetail">
<link:definition> 2406402 - Disclosure - Notes Payable and Financing Obligation - Hercules Notes Payable (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="NotesPayableAndFinancingObligationSummaryOfAggregateTotalFutureMinimumLeasePaymentsUnderFinancingObligationDetail" roleURI="http://www.revance.com/role/NotesPayableAndFinancingObligationSummaryOfAggregateTotalFutureMinimumLeasePaymentsUnderFinancingObligationDetail">
<link:definition> 2406404 - Disclosure - Notes Payable and Financing Obligation - Summary of Aggregate Total Future Minimum Lease Payments under the Financing Obligation (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="NotesPayableAndFinancingObligationTables" roleURI="http://www.revance.com/role/NotesPayableAndFinancingObligationTables">
<link:definition> 2306301 - Disclosure - Notes Payable and Financing Obligation (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="SubsequentEvents" roleURI="http://www.revance.com/role/SubsequentEvents">
<link:definition> 2113100 - Disclosure - Subsequent Events </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="SubsequentEventsDetails" roleURI="http://www.revance.com/role/SubsequentEventsDetails">
<link:definition> 2413401 - Disclosure - Subsequent Events (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.revance.com/role/SummaryOfSignificantAccountingPolicies">
<link:definition> 2102100 - Disclosure - Summary of Significant Accounting Policies </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.revance.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition> 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="Warrants" roleURI="http://www.revance.com/role/Warrants">
<link:definition> 2110100 - Disclosure - Warrants </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="WarrantsAdditionalInformationDetail" roleURI="http://www.revance.com/role/WarrantsAdditionalInformationDetail">
<link:definition> 2410401 - Disclosure - Warrants - Additional Information (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="rvnc_A2013NotesEmbeddedDerivativeLiabilityMember" name="A2013NotesEmbeddedDerivativeLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="rvnc_A2013NotesWarrantMember" name="A2013NotesWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
<xsd:element id="rvnc_AccruedMilestoneObligations" name="AccruedMilestoneObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
<xsd:element id="rvnc_AgreementSettlementUpfrontPayment" name="AgreementSettlementUpfrontPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
<xsd:element id="rvnc_AmortizationOfDebtDiscount" name="AmortizationOfDebtDiscount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
<xsd:element id="rvnc_CashCashEquivalentsandInvestments" name="CashCashEquivalentsandInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
<xsd:element id="rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum" name="CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
<xsd:element id="rvnc_ChangeinFairValueofConvertiblePreferredStockWarrant" name="ChangeinFairValueofConvertiblePreferredStockWarrant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
<xsd:element id="rvnc_CommonStockCapitalSharesReservedforFutureIssuancePercentageIncrease" name="CommonStockCapitalSharesReservedforFutureIssuancePercentageIncrease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
<xsd:element id="rvnc_CommonStockValueRemainingAmountAvailabletobeSold" name="CommonStockValueRemainingAmountAvailabletobeSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
<xsd:element abstract="true" id="rvnc_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
<xsd:element id="rvnc_ConversionOfPreferredStockWarrantsToCommonStockWarrants" name="ConversionOfPreferredStockWarrantsToCommonStockWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
<xsd:element id="rvnc_ConvertibleNotesTextBlock" name="ConvertibleNotesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
<xsd:element id="rvnc_DebtInstrumentFinalPaymentAmount" name="DebtInstrumentFinalPaymentAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
<xsd:element id="rvnc_DebtInstrumentNumberofMonthlyPayments" name="DebtInstrumentNumberofMonthlyPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="rvnc_DerivativeLiabilitySettlementMember" name="DerivativeLiabilitySettlementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="rvnc_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
<xsd:element id="rvnc_EquipmentPurchasedbyThirdParty" name="EquipmentPurchasedbyThirdParty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
<xsd:element id="rvnc_EquipmentPurchasedbyThirdPartyIncreaseDuringPeriod" name="EquipmentPurchasedbyThirdPartyIncreaseDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="rvnc_EssexNotesMember" name="EssexNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
<xsd:element id="rvnc_ExercisePricePerShare" name="ExercisePricePerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration"/>
<xsd:element id="rvnc_ExtinguishmentofWarrantLiabilityUponExerciseofPutOption" name="ExtinguishmentofWarrantLiabilityUponExerciseofPutOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
<xsd:element id="rvnc_FinancingLeaseObligationNoncurrentNetofCurrentPortion" name="FinancingLeaseObligationNoncurrentNetofCurrentPortion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
<xsd:element id="rvnc_FinancingObligationCurrent" name="FinancingObligationCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
<xsd:element id="rvnc_FinancingObligationFutureMinimumPaymentsDue" name="FinancingObligationFutureMinimumPaymentsDue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
<xsd:element id="rvnc_FinancingObligationFutureMinimumPaymentsDueinFourYears" name="FinancingObligationFutureMinimumPaymentsDueinFourYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
<xsd:element id="rvnc_FinancingObligationFutureMinimumPaymentsDueinThreeYears" name="FinancingObligationFutureMinimumPaymentsDueinThreeYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
<xsd:element id="rvnc_FinancingObligationFutureMinimumPaymentsDueinTwoYears" name="FinancingObligationFutureMinimumPaymentsDueinTwoYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
<xsd:element id="rvnc_FinancingObligationFutureMinimumPaymentsNextTwelveMonths" name="FinancingObligationFutureMinimumPaymentsNextTwelveMonths" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
<xsd:element id="rvnc_GainLossOnSettlementInExchangeOfPreferredStockWarrants" name="GainLossOnSettlementInExchangeOfPreferredStockWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
<xsd:element id="rvnc_GainLossonDerivativeInstrumentsContractNetPretax" name="GainLossonDerivativeInstrumentsContractNetPretax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="rvnc_HerculesNotesPayableMember" name="HerculesNotesPayableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
<xsd:element id="rvnc_InterestExpenseCapitalized" name="InterestExpenseCapitalized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
<xsd:element id="rvnc_InterestExpenseConvertibleNotes" name="InterestExpenseConvertibleNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
<xsd:element id="rvnc_InterestExpenseDebtIssuanceCosts" name="InterestExpenseDebtIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
<xsd:element id="rvnc_InterestExpenseWarrantandDerivativeRelatedDebtDiscounts" name="InterestExpenseWarrantandDerivativeRelatedDebtDiscounts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
<xsd:element id="rvnc_IssuanceOfCommonStockUponNetExerciseOfWarrants" name="IssuanceOfCommonStockUponNetExerciseOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
<xsd:element id="rvnc_IssuanceOfCommonStockWarrants" name="IssuanceOfCommonStockWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
<xsd:element id="rvnc_IssuanceOfConvertiblePreferredStockWarrants" name="IssuanceOfConvertiblePreferredStockWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
<xsd:element id="rvnc_LeaseMaturityTerm" name="LeaseMaturityTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
<xsd:element id="rvnc_LongTermDebtPrepayment" name="LongTermDebtPrepayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
<xsd:element id="rvnc_MaximumCommissionBasedonGrossSalesofSecondaryOffering" name="MaximumCommissionBasedonGrossSalesofSecondaryOffering" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
<xsd:element abstract="true" id="rvnc_MedicisPharmaceuticalCorporationMember" name="MedicisPharmaceuticalCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="rvnc_NonEmployeeStockOptionMember" name="NonEmployeeStockOptionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
<xsd:element id="rvnc_NoncashDeferredInitialPublicOfferingCosts" name="NoncashDeferredInitialPublicOfferingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
<xsd:element id="rvnc_NoncashInterestExpense" name="NoncashInterestExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
<xsd:element id="rvnc_PercentageOfOriginalPurchaseAmountOfLeasedAssetAtEndOfLease" name="PercentageOfOriginalPurchaseAmountOfLeasedAssetAtEndOfLease" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
<xsd:element id="rvnc_ProceedsFromIssuanceofFollowOnOffering" name="ProceedsFromIssuanceofFollowOnOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="rvnc_ProceedsSharingArrangementMember" name="ProceedsSharingArrangementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
<xsd:element id="rvnc_ProceedsfromIssuanceofCommonStockMaximumProceedsAllowedonSecondaryOffering" name="ProceedsfromIssuanceofCommonStockMaximumProceedsAllowedonSecondaryOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
<xsd:element id="rvnc_RevaluationOfConvertibleRedeemablePreferredStockWarrants" name="RevaluationOfConvertibleRedeemablePreferredStockWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
<xsd:element id="rvnc_ScheduleofFutureMinimumLeasePaymentsFinancingObligationTableTextBlock" name="ScheduleofFutureMinimumLeasePaymentsFinancingObligationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
<xsd:element id="rvnc_SettlementAgreementAmount" name="SettlementAgreementAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="rvnc_SettlementAndTerminationLineItems" name="SettlementAndTerminationLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
<xsd:element id="rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants" name="StockIssuedDuringPeriodSharesExerciseofWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
<xsd:element id="rvnc_TerminationofStockOptionRepurchaseRightNoncash" name="TerminationofStockOptionRepurchaseRightNoncash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" name="TwoThousandAndFourteenEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="rvnc_TwoThousandAndFourteenEquityIncentivePlanMember" name="TwoThousandAndFourteenEquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="rvnc_TwoThousandAndFourteenInducementPlanMember" name="TwoThousandAndFourteenInducementPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="rvnc_TwoThousandFifteenAtTheMarketIssuanceSalesAgreementMember" name="TwoThousandFifteenAtTheMarketIssuanceSalesAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="rvnc_TwoThousandThirteenConvertibleNotesMember" name="TwoThousandThirteenConvertibleNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="rvnc_UnvestedRestrictedStockAwardsMember" name="UnvestedRestrictedStockAwardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
<xsd:element id="rvnc_WarrantsIssuedForPurchaseOfStockShares" name="WarrantsIssuedForPurchaseOfStockShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
<xsd:element id="rvnc_WarrantsTextBlock" name="WarrantsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
<xsd:element id="rvnc_WorkingCapitalSurplus" name="WorkingCapitalSurplus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
<xsd:element id="rvnc_WriteoffofFixedAssets" name="WriteoffofFixedAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
</xsd:schema>

8 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/29/24  Revance Therapeutics, Inc.        S-8         2/29/24    4:123K
 2/28/24  Revance Therapeutics, Inc.        10-K       12/31/23  110:12M
 2/28/23  Revance Therapeutics, Inc.        S-8         2/28/23    5:192K
 2/28/23  Revance Therapeutics, Inc.        10-K       12/31/22  109:14M
 2/28/22  Revance Therapeutics, Inc.        S-8         2/28/22    5:197K
 2/28/22  Revance Therapeutics, Inc.        10-K       12/31/21  106:12M
 2/25/21  Revance Therapeutics, Inc.        10-K       12/31/20  109:12M
 1/29/21  Revance Therapeutics, Inc.        S-8         1/29/21    3:137K
↑Top
Filing Submission 0001479290-15-000010   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Fri., Apr. 19, 8:58:19.3pm ET